Clinical Trial Update: Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab with or without fosbretabulin tromethamine in recurrent or persistent ovarian epithelial, fallopian tube, or peritoneal cav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Fosbretabulin tromethamine (fosbretabulin tromethamine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2017-07-12